Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cellsAna Valdehíta, Juan Carlos Prieto, Ana M. Bajo et al.|Molecular and Cellular Endocrinology|2008Cited by 56
Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancerAna Valdehíta, Marı́a J. Carmena, Ana M. Bajo et al.|Peptides|2010Cited by 54
Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3KIrene Gutiérrez‐Cañas, Marı́a J. Carmena, Marı́a G. Juarranz et al.|The Prostate|2004Cited by 49
Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptorsMarı́a G. Juarranz, Nieves Rodríguez‐Henche, Oscar R. Bolanos et al.|Cellular Signalling|2001Cited by 39
Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cellsAna Valdehíta, Ana M. Bajo, Marı́a J. Carmena et al.|Regulatory Peptides|2007Cited by 35